Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma patients after curative resection, a systematic review and meta-analysis

Digestive and Liver Disease

Volumn 48, Issue 11, 2016, Pages 1275-1282

  Wang, Haiqing ^a   Liu, Aixiang ^a   Bo, Wentao ^a   Feng, Xielin ^a   Hu, Yong ^a   Tian, Lang ^a   Zhang, Hui ^a   Tang, Xiaoli ^a  

^a SICHUAN CANCER HOSPITAL   (China)

Author keywords

Cytokine induced killer cells; Hepatectomy; Hepatocellular carcinoma; Immunotherapy

Indexed keywords

ALLERGY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CELL THERAPY; CLINICAL EFFECTIVENESS; COCHRANE LIBRARY; CYTOKINE INDUCED KILLER CELL; DISEASE FREE SURVIVAL; EMBASE; FEVER; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MEDLINE; META ANALYSIS; OVERALL SURVIVAL; PAIN; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCISEARCH; SURVIVAL RATE; SYSTEMATIC REVIEW; CARCINOMA, HEPATOCELLULAR; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; COMPLICATION; IMMUNOLOGY; IMMUNOTHERAPY; LIVER NEOPLASMS; PROCEDURES;

CARCINOMA, HEPATOCELLULAR; CYTOKINE-INDUCED KILLER CELLS; DISEASE-FREE SURVIVAL; HEPATECTOMY; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE;

EID: 84992497184     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2016.07.010     Document Type: Review

References (36)

1. [1] Ferlay, J., Soerjomataram, I., Dikshit, R., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer 136 (2015), E359–E386.
2. [2] Dhanasekaran, R., Venkatesh, S.K., Torbenson, M., et al. Clinical implications of basic research in hepatocellular carcinoma. Journal of Hepatology, 2015.
3. [3] Cucchetti, A., Qiao, G.L., Cescon, M., et al. Anatomic versus nonanatomic resection in cirrhotic patients with early hepatocellular carcinoma. Surgery 155 (2014), 512–521.
4. [4] Nault, J.C., De Reynies, A., Villanueva, A., et al. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology 145 (2013), 176–187.
5. [5] Roayaie, S., Obeidat, K., Sposito, C., et al. Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology 57 (2013), 1426–1435.
6. [6] Zhu, G.Q., Shi, K.Q., Yu, H.J., et al. Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis. Oncotarget 6 (2015), 18151–21861.
7. [7] Wang, J., He, X.D., Yao, N., et al. A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma. Canadian Journal of Gastroenterology 27 (2013), 351–363.
8. [8] Zhong, J.H., Li, H., Li, L.Q., et al. Adjuvant therapy options following curative treatment of hepatocellular carcinoma: a systematic review of randomized trials. European Journal of Surgical Oncology 38 (2012), 286–295.
9. [9] Schwartz, J.D., Schwartz, M., Mandeli, J., et al. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncology 3 (2002), 593–603.
10. [10] Prieto, J., Melero, I., Sangro, B., Immunological landscape and immunotherapy of hepatocellular carcinoma. Nature Reviews Gastroenterology & Hepatology, 2015.
11. [11] Greten, T.F., Wang, X.W., Korangy, F., Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches. Gut 64 (2015), 842–848.
12. [12] Xie, F., Zhang, X., Li, H., et al. Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. PLoS ONE, 7, 2012, e42879.
13. [13] Xu, L., Wang, J., Kim, Y., et al. A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma. OncoImmunology, 5, 2015, e1083671.
14. [14] Lee, J.H., Lim, Y.S., Yeon, J.E., et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology, 148, 2015 1383–91.e6.
15. [15] Yu, X., Zhao, H., Liu, L., et al. A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma. Journal of Clinical Immunology 34 (2014), 194–203.
16. [16] Pan, C.C., Huang, Z.L., Li, W., et al. Serum alpha-fetoprotein measurement in predicting clinical outcome related to autologous cytokine-induced killer cells in patients with hepatocellular carcinoma undergone minimally invasive therapy. Chinese Journal of Cancer 29 (2010), 596–602.
17. [17] Hui, D., Qiang, L., Jian, W., et al. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Digestive and Liver Disease 41 (2009), 36–41.
18. [18] Weng, D.S., Zhou, J., Zhou, Q.M., et al. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. Journal of Immunotherapy 31 (2008), 63–71.
19. [19] Takayama, T., Sekine, T., Makuuchi, M., et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356 (2000), 802–807.
20. [20] Deeks, J., Altman, D.G., Analysing data and undertaking meta-analyses. Higgins, J.P.T., Green, S., (eds.) Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011), 2011, The Cochrane Collaboration [chapter 9].
21. [21] Wang, H.Q., Yang, J., Yang, J.Y., et al. Bile leakage test in liver resection: a systematic review and meta-analysis. World Journal of Gastroenterology 19 (2013), 8420–8426.
22. [22] Jakel, C.E., Schmidt-Wolf, I.G., An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells. Expert Opinion on Biological Therapy 14 (2014), 905–916.
23. [23] Mesiano, G., Todorovic, M., Gammaitoni, L., et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opinion on Biological Therapy 12 (2012), 673–684.
24. [24] Sangiolo, D., Cytokine induced killer cells as promising immunotherapy for solid tumors. Journal of Cancer 2 (2011), 363–368.
25. [25] Schmidt, T.L., Negrin, R.S., Contag, C.H., A killer choice for cancer immunotherapy. Immunologic Research 58 (2014), 300–306.
26. [26] Wei, F., Rong, X.X., Xie, R.Y., et al. Cytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognition. Oncotarget, 2015.
27. [27] Han, R.X., Liu, X., Pan, P., et al. Effectiveness and safety of chemotherapy combined with dendritic cells co-cultured with cytokine-induced killer cells in the treatment of advanced non-small-cell lung cancer: a systematic review and meta-analysis. PLOS ONE, 9, 2014, e108958.
28. [28] Lin, T., Song, C., Chuo, D.Y., et al. Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study. Tumour Biology, 2015.
29. [29] Liu, K., Song, G., Hu, X., et al. A positive role of cytokine-induced killer cell therapy on gastric cancer therapy in a Chinese population: a systematic meta-analysis. Medical Science Monitor 21 (2015), 3363–3370.
30. [30] Pan, K., Li, Y.Q., Wang, W., et al. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients. Annals of Surgical Oncology 20 (2013), 4305–4311.
31. [31] Yin, J., Li, N., Han, Y., et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. Journal of Clinical Oncology 31 (2013), 3647–3655.
32. [32] Shi, M., Zhang, B., Tang, Z.R., et al. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World Journal of Gastroenterology 10 (2004), 1146–1151.
33. [33] Chen, B., Xu, X., Xiang, M., et al. Cytokine-induced killer cell combination with TACE in the treatment of hepatocellular cancers: a meta-analysis. Chinese-German Journal of Clinical Oncology 12 (2013), 459–467.
34. [34] Li, X., Dai, D., Song, X., et al. A meta-analysis of cytokine-induced killer cells therapy in combination with minimally invasive treatment for hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology 38 (2014), 583–591.
35. [35] Ma, Y., Xu, Y.C., Tang, L., et al. Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety. Experimental Hematology & Oncology, 1, 2012, 11.
36. [36] Zhong, J.H., Ma, L., Wu, L.C., et al. Adoptive immunotherapy for postoperative hepatocellular carcinoma: a systematic review. International Journal of Clinical Practice 66 (2012), 21–27.